<DOC>
	<DOCNO>NCT01412190</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Restylane Vital White administer injector device age skin face , hand décolletage .</brief_summary>
	<brief_title>Study Evaluate Restylane Vital Light Using Injector Device</brief_title>
	<detailed_description>The objective explore safety efficacy profile Restylane Vital White administer injector device one side face , one hand one side décolletage treat side face , hand side décolletage leave untreated . The face , hand décolletage evaluate separately efficacy safety parameter .</detailed_description>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Signed informed consent obtain Female subject 4065 year age , inclusive . Visible sign skin age face , hand décolletage ( e.g . reduce skin elasticity , reduce turgor , actinic elastosis , small large wrinkle ) accord Investigators opinion . Subjects must cooperative willing comply instruction procedure . Extensively photo damage age skin accord Investigators opinion . Active skin disease , inflammation related condition , infection , perioral dermatitis , seborrheic eczema rosacea face , hand décolletage . History active collagenosis ( e.g . systemic lupus , erythematosis , Rheumatic arthritis , skin systemic sclerosis ) Previous hypersensitivity hyaluronic acid . Concomitant therapy thrombolytic anticoagulant , take inhibitor platelet aggregation , within 2 week baseline visit . History cancerous precancerous lesion face , hand décolletage . Previous tissue augment therapy nonpermanent filler treatment botulinum toxin , aesthetic surgical therapy , laser treatment , mesotherapy , form peel face , hand décolletage within 12 month prior baseline visit . Use injectable revitalization preparation ( e.g . Hyal System® , Restylane Vital ) within 12 month prior baseline visit . Use retinoic acid within 6 month prior baseline visit . Previous concomitant treatment chemotherapy , immunosuppressive agent corticoid . History treatment permanent filling material . Pregnancy breast feed woman woman childbearing potential practicing adequate contraception . Participation clinical study within 30 day prior baseline visit plan participate another clinical study study period . Unrealistic expectation regard esthetic result treatment . Planned ongoing weight reduction program study . Known history drug alcohol abuse within 6 month prior baseline visit . Known hypersensitivity one component EMLA cream® . Any medical condition opinion Investigator make subject unsuitable inclusion ( e.g . severe chronic disease , malignancy , bleed disorder , skin disease etc ) . Other condition prevent subject enter study Investigator 's opinion e.g . subject anticipate unreliable , unable return followup visit , likely avoid prohibit treatment procedure incapable understanding information instruction . Nicotine use study stop within 12 month baseline visit . Study staff close relative study staff ( e.g . parent , child , sibling spouse ) .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Skin rejuvenation</keyword>
</DOC>